-
公开(公告)号：KR100321313B1
公开(公告)日：2002-08-13
申请号：KR1019980043425
申请日：1998-10-17
Applicant: 한국과학기술연구원
Abstract: 본 발명은 류코트리엔 생성 저해활성을 가지는 신이 (Magnoliae flos) 추출물 및 신이로부터 분리한 리그난 화합물에 관한 것으로, 신이를 유기용매로 추출하여 얻어지는 본 발명의 신이 추출물 및 이로부터 분리되는 하기 화학식 1 내지 화학식 7의 리그난 화합물은 류코트리엔 생성 저해제로서 류코트리엔과 관련된 질환의 예방, 치료 및 치료보조제로 유용하게 사용될 수 있다.
[화학식 1]
[화학식 2]
[화학식 3]
[화학식 4]
[화학식 5]
[화학식 6]
[화학식 7]-
公开(公告)号：KR100270912B1
公开(公告)日：2000-10-16
申请号：KR1019990024335
申请日：1999-06-25
Applicant: 한국과학기술연구원
IPC: A61K31/09
Abstract: PURPOSE: Schizandrin having antagonistic activity on a platelet activating factor receptor isolated from Schisandrae fructus, a pharmaceutical composition containing the compound, pharmaceutically acceptable carrier and excipient and their use are provided. Therefore the composition can be used for treatment and prevention of inflammatory disease related to a platelet activating factor. CONSTITUTION: An antagonist on a platelet activating factor receptor contains schizandrin A, B or C of formula 3 isolated from Schisandrae fructus as an effective component. In formula, a compound in which R1, R2, R3 and R4 are respectively CH3O is schizandrin A; a compound in which R1 and R2 are respectively CH3O, and R3 and R4 are connected to OCH2O is schizandrin B; and a compound in which R3 and R4 are connected to OCH2O is schizandrin C. A pharmaceutical composition for treatment and prevention of inflammatory disease related to a platelet activating factor contains the schizandrin, pharmaceutically acceptable carrier and excipient.
Abstract translation: 目的：提供对从五味子分离的血小板活化因子受体具有拮抗作用的五味子，含有该化合物，药学上可接受的载体和赋形剂的药物组合物及其用途。 因此，该组合物可用于治疗和预防与血小板激活因子相关的炎性疾病。 构成：血小板活化因子受体上的拮抗剂含有从五味子中分离的式3的五味子素A，B或C作为有效成分。 在式中，R 1，R 2，R 3和R 4分别为CH 3 O的化合物为五味子二; 其中R1和R2分别为CH3O，R3和R4连接到OCH2O的化合物是五味子二; 和其中R 3和R 4连接到OCH 2 O的化合物是五味子三嗪C.用于治疗和预防与血小板活化因子相关的炎性疾病的药物组合物含有五味子三糖，药学上可接受的载体和赋形剂。
-
公开(公告)号：KR1020000040361A
公开(公告)日：2000-07-05
申请号：KR1019980055981
申请日：1998-12-18
Applicant: 한국과학기술연구원
IPC: A61K31/035
Abstract: PURPOSE: A pharmaceutical composition containing essential oil as an active principle for inhibiting production of leukotriene is useful for prevention and treatment of the diseases related with the activity of leukotriene such as asthma, cystic fibrosis, septic shock, cardiac anaphylaxis, cerebral vasospasm, psoriasis, endotoxemia, myocardial ischemia, etc.. CONSTITUTION: A main component of the essential oil is more than one compound selected from (-)-menthol, (+)-limonene, alpha-terpinene, gamma-terpinene, terpineol, beta-myrcene, (+or-)-linalool, geraniol, citral, beta-cyclocitral, eugenol, safrol, (+)-alpha-pinene, (-)-alpha-pinene and (+)-cis-verbenol.
Abstract translation: 目的：含有精油作为抑制白细胞三烯生成的活性成分的药物组合物可用于预防和治疗与白细胞三烯的活性有关的疾病，例如哮喘，囊性纤维化，败血性休克，心脏过敏反应，脑血管痉挛，牛皮癣， 内毒素血症，心肌缺血等。组成：精油的主要成分是选自（ - ） - 薄荷醇，（+） - 柠檬烯，α-萜品烯，γ-萜品烯，萜品醇，β-月桂烯， （+或 - ） - 芳樟醇，香叶醇，柠檬醛，β-环咔唑，丁子香酚，safrol，（+） - 蒎烯，（ - ） - 蒎烯和（+） - 顺式 -
-
-
-
Search Results
24
records
(took 0.036 seconds)
